				Application No. 08/286,189	Applicant(s) Sanhueza et al.			
		Notice of Refere	ences Cited			Group Art Unit 1648		
			U.S	S. PATENT DOCUMENTS				
_			DATE	NAMI			CLASS	SUBCLASS
*		DOCUMENT NO.	DATE					
	Α							
	В							
	С							
	D							
	E							
	F							
	G							
	Н							
_								
	J							
	K	(
	L							
	N	M						<u> </u>
			FOI	REIGN PATENT DOCUMENT			CLASS	SUBCLASS
*		DOCUMENT NO.	DATE	COUNTRY	NA	ME 	CEAGG	
	r	N						
	(0						
	1	Р						
r	-	a						
\vdash	+	R						
H		S						
-	+							
-		Т		NON-PATENT DOCUMENTS	3			
	-							DATE
	*	LL II C. B. "Broanceto	for a respiratory syncy	UMENT (Including Author, Title, Source, and Pertinent Pages)				
	×	U						1994
		v 22:715-718.		virus vaccines: Can we in				1993
}	x	Toms, G. L., "Respira"	tory syncytial virus-hov	v soon can we have a vac	ccine?", Arcl	n. Dis. Childhood	72:1-3.	1995
	×	and parainfluenza viru	Murphy, B. R., et al., "An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines", Vir. Res. 32:13-36.					

^{*}A copy of this reference is not being furnished with this Office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)

				Application No. 08/286,189	Applicant	Sanhueza	et al.		
	Notice of References Cited			Examiner Jeffrey S. Parkin, Ph.D.		Group Art Unit 1648 Page 2		ge 2 of 2	
			U.S	S. PATENT DOCUMENTS					
		DOCUMENT NO.	DATE	NAM	IE 		CLASS	SUBCLASS	
A									
B	-								
 C	-								
D	-								
E	-								
_ F	-								
G	\vdash								
Н	+-								
-									
_	╁								
J									
K	+								
L	- -								
N	n		FOI	REIGN PATENT DOCUMEN	тѕ			T	
Т	\neg	DOCUMENT NO.	DATE	COUNTRY	N/	AME	CLASS	SUBCLASS	
+.	+	DOCOMENT NO.							
+	N C								
+	0						<u> </u>		
+	P								
+	<u>α</u>								
+	R							,	
-	S								
	T			NON-PATENT DOCUMENT	s	-			
_				Adabas Title Source and Pertin	ent Pages)			DATE	
	U	Salkind, A. R. and N. J. Roberts, Jr., "Recent observations regarding the pathogenesis of recurrent respiratory syncytial virus infections: implications for vaccine development", Vaccine 10(8):519-523.							
	٧								
	w								
	x								

U. S. Patent and Trademark Office PTO-892 (Rev. 9-95)